South Korea
· Delayed Price · Currency is KRW JW Lifescience Statistics
Total Valuation
JW Lifescience has a market cap or net worth of KRW 188.14 billion. The enterprise value is 226.97 billion.
| Market Cap | 188.14B |
| Enterprise Value | 226.97B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
JW Lifescience has 15.48 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 15.48M |
| Shares Outstanding | 15.48M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 0.96% |
| Float | 8.56M |
Valuation Ratios
The trailing PE ratio is 4.18.
| PE Ratio | 4.18 |
| Forward PE | n/a |
| PS Ratio | 0.77 |
| PB Ratio | 0.95 |
| P/TBV Ratio | 1.55 |
| P/FCF Ratio | 5.03 |
| P/OCF Ratio | 3.82 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.57, with an EV/FCF ratio of 6.06.
| EV / Earnings | 5.05 |
| EV / Sales | 0.93 |
| EV / EBITDA | 3.57 |
| EV / EBIT | 4.78 |
| EV / FCF | 6.06 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.35 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.24 |
| Debt / FCF | 1.74 |
| Interest Coverage | 17.69 |
Financial Efficiency
Return on equity (ROE) is 25.29% and return on invested capital (ROIC) is 9.73%.
| Return on Equity (ROE) | 25.29% |
| Return on Assets (ROA) | 7.74% |
| Return on Invested Capital (ROIC) | 9.73% |
| Return on Capital Employed (ROCE) | 14.95% |
| Revenue Per Employee | 808.40M |
| Profits Per Employee | 149.38M |
| Employee Count | 301 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 6.24 |
Taxes
In the past 12 months, JW Lifescience has paid 15.17 billion in taxes.
| Income Tax | 15.17B |
| Effective Tax Rate | 25.22% |
Stock Price Statistics
The stock price has increased by +2.82% in the last 52 weeks. The beta is 0.42, so JW Lifescience's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +2.82% |
| 50-Day Moving Average | 11,590.60 |
| 200-Day Moving Average | 11,199.40 |
| Relative Strength Index (RSI) | 55.12 |
| Average Volume (20 Days) | 39,133 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, JW Lifescience had revenue of KRW 243.33 billion and earned 44.96 billion in profits. Earnings per share was 2,903.66.
| Revenue | 243.33B |
| Gross Profit | 61.28B |
| Operating Income | 36.46B |
| Pretax Income | 60.13B |
| Net Income | 44.96B |
| EBITDA | 52.55B |
| EBIT | 36.46B |
| Earnings Per Share (EPS) | 2,903.66 |
Balance Sheet
The company has 26.46 billion in cash and 65.30 billion in debt, giving a net cash position of -38.83 billion or -2,507.92 per share.
| Cash & Cash Equivalents | 26.46B |
| Total Debt | 65.30B |
| Net Cash | -38.83B |
| Net Cash Per Share | -2,507.92 |
| Equity (Book Value) | 198.81B |
| Book Value Per Share | 12,839.24 |
| Working Capital | 28.50B |
Cash Flow
In the last 12 months, operating cash flow was 49.28 billion and capital expenditures -11.85 billion, giving a free cash flow of 37.43 billion.
| Operating Cash Flow | 49.28B |
| Capital Expenditures | -11.85B |
| Free Cash Flow | 37.43B |
| FCF Per Share | 2,417.07 |
Margins
Gross margin is 25.19%, with operating and profit margins of 14.98% and 18.48%.
| Gross Margin | 25.19% |
| Operating Margin | 14.98% |
| Pretax Margin | 24.71% |
| Profit Margin | 18.48% |
| EBITDA Margin | 21.60% |
| EBIT Margin | 14.98% |
| FCF Margin | 15.38% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 4.12%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 4.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 17.22% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 4.15% |
| Earnings Yield | 23.90% |
| FCF Yield | 19.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 20, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Apr 20, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
JW Lifescience has an Altman Z-Score of 2.63 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.63 |
| Piotroski F-Score | 7 |